Skip to Content

Press Releases

Date Title and Summary Additional Formats
Mar 11, 2020
Fluidigm’s First Mass Cytometry Center of Excellence in Singapore and Southeast Asia for Advancement of Highly Multiplexed Tissue Imaging in Translational and Clinical Research SOUTH SAN FRANCISCO, Calif. , March 11, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative
Mar 10, 2020
Driving Cell Capture to Insight with Precision, Speed and Simplicity to Accelerate Biomarker and Therapeutic Development SOUTH SAN FRANCISCO, Calif. , March 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life
Mar 03, 2020
Enabling Low-Cost, High-Volume Sequencing of Drug-Resistant Pathogens for Hospital Infection Control and Surveillance SOUTH SAN FRANCISCO, Calif. and HINXTON, United Kingdom , March 03, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an industry leader in microfluidics technology, and
Feb 26, 2020
Acquisition to expand Fluidigm’s industry-leading mass cytometry capabilities and address flow cytometry markets with the addition of fully automated sample prep SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools
Feb 12, 2020
SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that Chris Linthwaite , President and Chief Executive Officer, will
Feb 10, 2020
Fourth quarter revenue of $32.4 million Full year 2019 revenue increased 4 percent to $117.2 million ; full year mass cytometry revenue increased 23 percent Landmark Nature publication demonstrates potential clinical value of using Imaging Mass Cytometry Covance selects Fluidigm CyTOF technology to
Feb 10, 2020
New Center of Excellence to Advance Highly Multiplexed Tissue Imaging in Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
Feb 10, 2020
SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm (Nasdaq:FLDM) today announced that Covance, the drug development business of LabCorp® (NYSE: LH), a leading global life sciences company, has selected Fluidigm’s CyTOF® technology and the industry-leading Maxpar® Direct™
Jan 20, 2020
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced that a new landmark study demonstrates the potential for Imaging Mass Cytometry™ (IMC™) on the Hyperion™ Imaging System
Jan 14, 2020
Fourth quarter preliminary revenue of $32.0-32.4 million Fiscal year preliminary revenue of $116.7-117.2 million Mass cytometry revenue increased approximately 23 percent for the full fiscal year SOUTH SAN FRANCISCO, Calif. , Jan. 14, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM)